Home / Inspections / 1200624

FDA Inspection 1200624 — Roswell Park Cancer Institute Corporation. Div. of Pathology

Roswell Park Cancer Institute Corporation. Div. of Pathology — FEI 1372120

The FDA completed an inspection of Roswell Park Cancer Institute Corporation. Div. of Pathology on March 13, 2023 in Buffalo, NY. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Biologics.

Inspection Details

Classification
No Action Indicated (NAI) (NAI)
End Date
March 13, 2023
Fiscal Year
2023
Product Type
Biologics
Project Area
Blood and Blood Products
Location
Buffalo, NY (United States)

Facility

Other inspections at this facility

  • 1284298 (NAI Fri Sep 19 2025 00:00:00 GMT+0000 (Coordinated Universal Time))
  • 1084076 (NAI Fri Mar 01 2019 00:00:00 GMT+0000 (Coordinated Universal Time))
  • 998259 (NAI Fri Jan 13 2017 00:00:00 GMT+0000 (Coordinated Universal Time))
  • 908088 (NAI Fri Dec 19 2014 00:00:00 GMT+0000 (Coordinated Universal Time))
  • 821892 (NAI Fri Mar 01 2013 00:00:00 GMT+0000 (Coordinated Universal Time))

FDA data resources